When Vical Incorporated (NASDAQ:VICL) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happening in the industry ...

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Vical has received a distressing ...

Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 1/2 trial of its Vaxfectin genital herpes vaccine – a therapeutic inoculation that’s melded vaccine ...

SAN DIEGO, April 14, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of European Patent EP1587816, which extends coverage for TransVax™, the company's ...

Vical Incorporated’s VICL experimental antifungal candidate, VL-2397 (also known as ASP2397), received the qualified infectious disease product (QIDP) designation from the FDA for the treatment of ...

Vical's quiet period ended today with loud wailing from its shareholders. Just 10 days ago, the company announced its second-quarter results. At the time, Vical said it would limit interaction with ...

SAN DIEGO, Dec. 5, 2012 -- Vical Incorporated (Nasdaq:VICL) announced today a worldwide, nonexclusive license of its patented Vaxfectin® adjuvant to Cyvax, Inc., a privately held vaccine development ...

SAN DIEGO, Feb. 24, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that Vijay B. Samant, President and Chief Executive Officer, will provide an overview of the company's ...

Cowen & Co. maintained a "neutral" rating on Vical after the company briefed analysts on the status of its vaccine development programs. "While Vical's early programs continue to advance, the lack of ...

A gene therapy originally developed by San Diego-based Vical for growing new blood vessels in legs damaged by blood clots failed to prevent leg amputations and death in a Phase 3 trial of the ...

Vical (Nasdaq: VICL) reported earnings on Feb. 8. Here are the numbers you need to know. The 10-second takeaway For the quarter ended Dec. 31 (Q4), Vical missed estimates on revenues and exceeded ...